Onxeo SA
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Onxeo SA (C4X) - Total Assets
Latest total assets as of December 2024: €17.93 Million EUR
Based on the latest financial reports, Onxeo SA (C4X) holds total assets worth €17.93 Million EUR as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Onxeo SA - Total Assets Trend (2013–2024)
This chart illustrates how Onxeo SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Onxeo SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Onxeo SA's total assets of €17.93 Million consist of 25.5% current assets and 74.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 6.6% |
| Accounts Receivable | €1.72 Million | 9.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €11.97 Million | 66.8% |
Asset Composition Trend (2013–2024)
This chart illustrates how Onxeo SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Onxeo SA's current assets represent 25.5% of total assets in 2024, a decrease from 92.7% in 2013.
- Cash Position: Cash and equivalents constituted 6.6% of total assets in 2024, down from 22.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 66.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 66.8% of total assets.
Onxeo SA Competitors by Total Assets
Key competitors of Onxeo SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Onxeo SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Onxeo SA generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Onxeo SA is currently not profitable relative to its asset base.
Onxeo SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.25 | 1.17 | 1.82 |
| Quick Ratio | 0.25 | 1.17 | 1.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-13.77 Million | € 1.86 Million | € 5.08 Million |
Onxeo SA - Advanced Valuation Insights
This section examines the relationship between Onxeo SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.01 |
| Latest Market Cap to Assets Ratio | 2.78 |
| Asset Growth Rate (YoY) | -49.2% |
| Total Assets | €17.93 Million |
| Market Capitalization | $49.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Onxeo SA's assets at a significant premium ( 2.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Onxeo SA's assets decreased by 49.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Onxeo SA (2013–2024)
The table below shows the annual total assets of Onxeo SA from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €17.93 Million | -49.17% |
| 2023-12-31 | €35.27 Million | -18.13% |
| 2022-12-31 | €43.09 Million | -18.80% |
| 2021-12-31 | €53.06 Million | +14.10% |
| 2020-12-31 | €46.51 Million | +23.59% |
| 2019-12-31 | €37.63 Million | -40.51% |
| 2018-12-31 | €63.25 Million | -18.99% |
| 2017-12-31 | €78.07 Million | -37.59% |
| 2016-12-31 | €125.10 Million | -3.20% |
| 2015-12-31 | €129.24 Million | -14.98% |
| 2014-12-31 | €152.00 Million | +757.18% |
| 2013-12-31 | €17.73 Million | -- |